VFEND 50 MG FILM-COATED TABLETS Israel - English - Ministry of Health

vfend 50 mg film-coated tablets

pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 50 mg - voriconazole - voriconazole - treatment of:- invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei)- serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

VFEND 200 MG FILM-COATED TABLETS Israel - English - Ministry of Health

vfend 200 mg film-coated tablets

pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 200 mg - voriconazole - voriconazole - treatment of: - invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei),- serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

VFEND 200 MG POWDER FOR SOLUTION FOR INFUSION Israel - English - Ministry of Health

vfend 200 mg powder for solution for infusion

pfizer pfe pharmaceuticals israel ltd - voriconazole - powder for solution for infusion - voriconazole 200 mg/vial - voriconazole - voriconazole - treatment of :- invasive aspergillosis fluconazole-resistant serious invasive candida infections (including c. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

VFEND 40 MGML POWDER FOR ORAL SUSPENSION Israel - English - Ministry of Health

vfend 40 mgml powder for oral suspension

pfizer pfe pharmaceuticals israel ltd - voriconazole - powder for suspension - voriconazole 40 mg/ml - voriconazole - voriconazole - treatment of : - invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Mysoline 250mg Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

mysoline 250mg tablets

laboratoires serb - primidone - tablet - 250 milligram(s) - barbiturates and derivatives; primidone

Sporanox 100 mg Capsules Ireland - English - HPRA (Health Products Regulatory Authority)

sporanox 100 mg capsules

pco manufacturing ltd. - itraconazole - capsule, hard - 100 milligram(s) - triazole derivatives; itraconazole

Voriconazole Pfizer 50 mg film-coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

voriconazole pfizer 50 mg film-coated tablets

pfizer healthcare ireland - voriconazole - film-coated tablet - 50 milligram(s) - triazole derivatives; voriconazole

Voriconazole Teva 200 mg Film-coated Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

voriconazole teva 200 mg film-coated tablets

teva pharma b.v. - voriconazole - film-coated tablet - 200 milligram(s) - triazole derivatives; voriconazole

Voriconazole Accord European Union - English - EMA (European Medicines Agency)

voriconazole accord

accord healthcare s.l.u. - voriconazole - aspergillosis; candidiasis; mycoses - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.voriconazole accord should be administered primarily to patients with progressive, possibly life-threatening infections.

Voriconazole Hikma (previously Voriconazole Hospira) European Union - English - EMA (European Medicines Agency)

voriconazole hikma (previously voriconazole hospira)

hikma farmaceutica (portugal) s.a. - voriconazole - bacterial infections and mycoses; aspergillosis; candidiasis - antimycotics for systemic use - voriconazole is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct)recipients.